Solid Biosciences (SLDB) Research Coverage Started at Chardan Capital

Chardan Capital began coverage on shares of Solid Biosciences (NASDAQ:SLDB) in a report released on Wednesday. The brokerage set a “buy” rating and a $40.00 price target on the stock. Chardan Capital’s price target indicates a potential upside of 67.64% from the stock’s previous close.

A number of other research firms have also recently commented on SLDB. Leerink Swann began coverage on shares of Solid Biosciences in a research note on Tuesday. They issued an “outperform” rating and a $36.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Solid Biosciences in a research note on Tuesday. They issued a “neutral” rating and a $28.00 target price for the company. Goldman Sachs Group began coverage on shares of Solid Biosciences in a research note on Tuesday. They issued a “neutral” rating and a $31.00 target price for the company. Nomura began coverage on shares of Solid Biosciences in a research note on Tuesday. They issued a “buy” rating and a $52.00 target price for the company. Finally, Instinet began coverage on shares of Solid Biosciences in a research note on Tuesday. They issued a “buy” rating and a $52.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Solid Biosciences currently has a consensus rating of “Buy” and a consensus target price of $39.83.

Shares of Solid Biosciences (NASDAQ:SLDB) opened at $23.86 on Wednesday. Solid Biosciences has a 12 month low of $19.12 and a 12 month high of $29.25.

In other Solid Biosciences news, Director Life Sciences Maste Perceptive acquired 1,020,000 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was acquired at an average cost of $16.22 per share, for a total transaction of $16,544,400.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

WARNING: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/solid-biosciences-sldb-research-coverage-started-at-chardan-capital.html.

Solid Biosciences Company Profile

Solid Biosciences, LLC is a life science company. The Company focuses on developing therapies for Duchenne muscular dystrophy (DMD). It is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD.

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply